Effects of mometasone furoate/formoterol fumarate fixed-dose combination formulation on chronic obstructive pulmonary disease (COPD): results from a 52-week Phase III trial in subjects with moderate-to-very severe COPD.

Int J Chron Obstruct Pulmon Dis · 2012 · PMC3276257 · PMID 22334769

Europe PMC DOI

hedged sentence

0.0620

closest p · 1.2× alpha

0.0620

boldest claim

The sentences

marginally significantP = 0.062so close (0.05 < p ≤ 0.1)

However, the difference between MF/F 400/10 μg and F 10 μg (49 mL) was marginally significant for the pre-specified LOCF analysis ( P = 0.062).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.